Article Information
History
- April 3, 2017.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- W. S. DeWitt1*,
- K. K. Quan2,
- D. Wilburn3,
- A. Sherwood1,
- M. Vignali1,
- S. C. De Rosa4,
- C. L. Day5,
- T. J. Scriba6,
- H. S. Robins1,4,
- W. Swanson3,
- R. O. Emerson1 and
- C. Seshadri2
- 1Adaptive Biotechnologies, Seattle, USA
- 2Department of Medicine, University of Washington, Seattle, USA
- 3Department of Genome Sciences, University of Washington, Seattle, USA
- 4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
- 5Department of Microbiology and Immunology, Emory University School of Medicine and Emory Vaccine Center, Atlanta, USA
- 6South African Tuberculosis Vaccine Initiative and Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
- Corresponding author: Chetan Seshadri, M.D., University of Washington Medical Center, 750 Republican Street, Suite E663, Seattle, WA 98109, Email: seshadri{at}u.washington.edu, Phone: 206-543-6709; Fax: 206-616-4898
Conflict of Interest Statement: H.S.R has full-time employment, equity ownership and patents & royalties at Adaptive Biotechnologies Corporation. R.O.E, M.V, A.S, and W.S.D have full-time employment and equity ownership at Adaptive Biotechnologies Corporation